Ph.D., Associate Professor

Research Interests:Focused on lipid metabolism disorders, encompassing foundational research on fatty liver disease, diabetes, and obesity. Current research aims at identifying new targets and elucidating the mechanisms of metabolic diseases, specifically in fat development, liver metabolism, and muscle aging. The lab has developed various application platforms based on biological enzymology (including RNA-seq, metabolomics, siRNA, and macromolecular synthesis) to create a comprehensive system for target screening, modification, process optimization, and multiple pharmacological evaluations.

Dr. Shenglong Zhu obtained his Ph.D. from Jiangnan University in June 2018. From September 2018 to October 2019, he conducted postdoctoral research at the Chinese University of Hong Kong. He joined Jiangnan University in October 2019 and is currently an Associate Professor at Wuxi Medical School, Jiangnan University.

Research Projects:Dr. Zhu currently leads several research projects, including:

·National Natural Science Foundation of China

·Major Projects in Translational Medicine Research in Wuxi

·Health Projects of the Science and Technology Bureau

Publications and Patents:He has published 14 SCI papers as the first or corresponding author in journals such aseBioMedicine,Cellular & Molecular Biology Letters, andCell Communication and Signaling. He has also designed and developed a series of recombinant protein drugs and small molecule drugs targeting non-alcoholic fatty liver disease, among other related conditions, resulting in over 20 international and domestic patent applications. Ten of these patents have been granted, with four already commercialized.

Professional Service:Dr. Zhu serves as an editorial board member for theJournal of Exploratory Research in PharmacologyandJournal of Cancer Screening and Prevention, and as a reviewer for several international journals, includingAdipocyte,Natural Product Communications, andJournal of Applied Microbiology.